Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06647020 + avelumab
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PF-06647020 + avelumab is an investigational combination therapy for cancer, currently studied in advanced solid tumors, including platinum-resistant ovarian cancer. PF-06647020 (cofetuzumab pelidotin) is an antibody-drug conjugate (ADC) composed of a humanized anti-protein tyrosine kinase 7 (PTK7) monoclonal antibody linked to the auristatin microtubule inhibitor payload Aur0101 via a cleavable linker. It targets PTK7-expressing tumor cells, delivering the cytotoxic agent directly to induce mitotic arrest and apoptosis. Avelumab is a fully human IgG1 monoclonal antibody that blocks programmed cell death ligand 1 (PD-L1), preventing its interaction with PD‑1 and B7 receptors on T cells and antigen-presenting cells, thereby enhancing antitumor immune responses. The combination aims to leverage both direct cytotoxicity against tumor cells and immune-mediated antitumor activity[2][3][6][8].
- Brand names
- Bavencio
- Other names
- PF-06647020PF06647020PF 06647020cofetuzumab pelidotinavelumab
02
Targets
PTK7 (Protein tyrosine kinase 7)TUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on PF-06647020 + avelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06647020 + avelumab.